PIPELINE
For a better future SCM Lifescience will do its best
CoImmune Pipeline
Pipeline
pipeline
preclinical
Phase 1
clinical trial
clinical trial
Phase 2
clinical trial
clinical trial
Phase 3
clinical trial
clinical trial
Acute Lymphocytic Leukemia
Metastatic Kidney Cancer
Non-Hodgkins Lymphoma
Chronic Lymphocytic Leukemia
Colmmune is not our subsidiary company, but a company we invested in.
The purpose of this section is just to introduce the pipeline of Colmmune.
metastatic kidney cancer
01
mRNA-based dendritic cell anticancer vaccine
02
US Phase 2 clinical trial
Primary endpoint : overall survival rate during the trial period
(Overall Survival, OS)
-
Indicationmetastatic kidney cancer
-
Number of patients90 people
Group 1 : 1st standard treatment (Opdivo/Yervoy) + 2nd treatment (Lenvatinlb+Everolimus): 45 patients
Group 2 : Primary standard treatment (Opdivo/Yervoy) + Secondary treatment (Lenvatinlb+Everolimus) + CMN-001:45 people
-
Dosing regimenCMN-001: 1.2 X 107DCs
DC : Dendritic Cell, dendritic cell
-
Designrandomized,
Open label, multi-organ
clinical trial institution
